{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T19:29:04Z","timestamp":1769801344537,"version":"3.49.0"},"reference-count":119,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>The discovery of a mechanism by which bile acids (BAs) regulate fat synthesis by modulating the activation of the farnesoid X receptor (FXR) in the liver and intestines has highlighted the central role of BAs in triglyceride synthesis in the liver. FXR has been reported as a promising drug target for primary biliary cholangitis, metabolic-dysfunction-associated steatohepatitis, and metabolic-dysfunction-associated steatotic liver disease. A large number of FXR modulators with various chemotypes have been developed by many research groups. Although several FXR modulators are advancing into clinical trials, ongoing efforts aim to develop new FXR modulators that minimize the adverse effects associated with long-term administration. To develop drug candidates targeting FXR, various heterocyclic and\/or fused heteroaromatic rings have been employed as the core and\/or parts of the structures, out of which benzimidazole has been recognized as a valuable structural motif due to its synthetic accessibility and its versatility in constructing structurally diverse target molecules. Herein, we report on the development of FXR modulators incorporating benzimidazole as a fused heteroaromatic ring.<\/jats:p>","DOI":"10.3390\/molecules31030450","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T08:48:04Z","timestamp":1769590084000},"page":"450","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Review on Farnesoid X Receptor (FXR) Modulators Focusing on Benzimidazole Scaffold"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3940-5473","authenticated-orcid":false,"given":"Naoki","family":"Teno","sequence":"first","affiliation":[{"name":"Faculty of Clinical Nutrition, Hiroshima International University, Kure 737-0112, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9345-2377","authenticated-orcid":false,"given":"Keigo","family":"Gohda","sequence":"additional","affiliation":[{"name":"Computer-Aided Molecular Modeling Research Center Kansai (CAMM-Kansai), Nishinomiya 663-8241, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2506-0769","authenticated-orcid":false,"given":"Ko","family":"Fujimori","sequence":"additional","affiliation":[{"name":"Department of Pathobiochemistry, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Takatsuki 569-1094, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","article-title":"Identification of a nuclear receptor for bile acids","volume":"284","author":"Makishima","year":"1999","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","article-title":"Bile acids: Natural ligands for an orphan nuclear receptor","volume":"284","author":"Parks","year":"1999","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"37735","DOI":"10.1074\/jbc.R100035200","article-title":"Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism","volume":"276","author":"Lu","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000371670","article-title":"Bile acids as hormones: The FXR-FGF15\/19 pathway","volume":"33","author":"Kliewer","year":"2015","journal-title":"Dig. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cmet.2024.09.008","article-title":"Hepatic FXR-FGF4 is required for bile acid homeostasis via an FGFR4-LRH-1 signal node under cholestatic stress","volume":"37","author":"Song","year":"2025","journal-title":"Cell Metab."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Han, C.Y. (2018). Update on FXR biology: Promising therapeutic target?. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19072069"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/hep.29857","article-title":"Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism","volume":"68","author":"Pathak","year":"2018","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s13105-018-0610-8","article-title":"The ileal FGF15\/19 to hepatic FGFR4 axis regulates liver regeneration after partial hepatectomy in mice","volume":"4","author":"Li","year":"2018","journal-title":"J. Physiol. Biochem."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Katafuchi, T., and Makishima, M. (2022). Molecular basis of bile acid-FXR-FGF15\/19 signaling axis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23116046"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/14728222.2019.1559825","article-title":"The farnesoid X receptor: A potential target for expanding the therapeutic arsenal against kidney disease","volume":"23","author":"Masaoutis","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1021\/jm0002127","article-title":"Identification of a chemical tool for the orphan nuclear receptor FXR","volume":"43","author":"Maloney","year":"2000","journal-title":"J. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"9768","DOI":"10.1021\/acs.jmedchem.5b01161","article-title":"Discovery of 6-(4-{[5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic acid: A novel FXR agonist for the treatment of dyslipidemia","volume":"58","author":"Genin","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.24537","article-title":"Dual farnesoid X receptor\/TGR5 agonist INT-767 reduces liver injury in the Mdr2\u2212\/\u2212 (Abcb4\u2212\/\u2212) mouse cholangiopathy model by promoting biliary HCO3\u2212 output","volume":"54","author":"Baghdasaryan","year":"2011","journal-title":"Hepatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejphar.2013.10.048","article-title":"Effects of a farnesoid X receptor antagonist on hepatic lipid metabolism in primates","volume":"723","author":"Amano","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1126\/science.1072891","article-title":"A natural product that lowers cholesterol as an antagonist ligand for FXR","volume":"296","author":"Urizar","year":"2002","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1021\/acs.jmedchem.9b01621","article-title":"Nidufexor (LMB763), a novel FXR modulator for the treatment of nonalcoholic steatohepatitis","volume":"63","author":"Chianelli","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","article-title":"Tropifexor for nonalcoholic steatohepatitis: An adaptive, randomized, placebo-controlled phase 2a\/b trial","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"9960","DOI":"10.1021\/acs.jmedchem.7b00907","article-title":"Discovery of tropifexor (LJN452), a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH)","volume":"60","author":"Tully","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_19","unstructured":"Kinzel, O., Steeneck, C., and Kremoser, C. (2013). Novel FXR (NR1H4) Binding and Activity Modulating Compounds. (WO2013007387)."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1016\/j.bmcl.2016.05.070","article-title":"Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: Understanding and improving key determinants of pharmacological properties","volume":"26","author":"Kinzel","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: A phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/cpdd.960","article-title":"Safety, pharmacokinetics, pharmacodynamics, and formulation of liver-distributed farnesoid X-receptor agonist TERN-101 in healthy volunteers","volume":"10","author":"Wang","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1021\/acs.jmedchem.0c01955","article-title":"Discovery of LYS006, a potent and highly selective inhibitor of leukotriene A4 hydrolase","volume":"64","author":"Markert","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_24","unstructured":"Frias, J., Schmouder, R., Lawitz, E., Zhang, Y., Zhou, H., Badman, M.K., Ukomadu, C., Weiss, H.M., Zack, J., and Yadav, B. Clinical trial: A phase 2 randomised platform study to assess monotherapy and cmbination treatment regimens in metabolic dysfunction\u2013associated steatohepatitis. Aliment. Pharmacol. Ther., Online ahead of print."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1515\/mr-2024-0007","article-title":"Hormone-based pharmacotherapy for metabolic dysfunction-associated fatty liver disease","volume":"4","author":"Chui","year":"2024","journal-title":"Med. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1038\/s41591-025-03722-7","article-title":"TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: The randomized phase 2a DUET trial","volume":"31","author":"Noureddin","year":"2025","journal-title":"Nat. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.290.6.765","article-title":"Guggulipid for the treatment of hypercholesterolemia: A randomized controlled trial","volume":"290","author":"Szapary","year":"2003","journal-title":"JAMA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"8856","DOI":"10.1074\/jbc.M306422200","article-title":"The farnesoid X receptor controls gene expression in a ligand- and promoter-selective fashion","volume":"279","author":"Lew","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/hep.20092","article-title":"Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial","volume":"39","author":"Lindor","year":"2004","journal-title":"Hepatology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"17545","DOI":"10.1021\/acs.jmedchem.1c01017","article-title":"Recent advances in the medicinal chemistry of farnesoid X receptor","volume":"64","author":"Fang","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Tahlan, S., Kumar, S., and Narasimhan, B. (2019). Pharmacological significance of heterocyclic 1H-benzimidazole scaffolds: A review. BMC Chem., 13.","DOI":"10.1186\/s13065-019-0579-6"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/cbdd.12462","article-title":"Comprehensive review in current developments of benzimidazole-based medicinal chemistry","volume":"86","author":"Keri","year":"2015","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Sloop, J. (2023). Synthesis of heteroaromatic compounds. Molecules, 28.","DOI":"10.3390\/books978-3-0365-7562-9"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0021-9258(18)72045-0","article-title":"Some biological effects produced by benzimidazole and their reversal by purines","volume":"152","author":"Woolley","year":"1944","journal-title":"J. Biol. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1021\/cr60151a002","article-title":"The chemistry of the benzimidazoles","volume":"48","author":"Wright","year":"1951","journal-title":"Chem. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1021\/cr60265a005","article-title":"Benzimidazole nucleosides, nucleotides, and related derivatives","volume":"70","author":"Townsend","year":"1970","journal-title":"Chem. Rev."},{"key":"ref_37","first-page":"36","article-title":"Thiabendazole, a new broad spectrum anthelmintic","volume":"47","author":"Cuckler","year":"1961","journal-title":"J. Parasitol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1056\/NEJM199104043241406","article-title":"Omeprazole","volume":"324","author":"Maton","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2165\/00003495-199856060-00007","article-title":"Telmisartan","volume":"56","author":"McClellan","year":"1998","journal-title":"Drugs"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bcp.2010.09.023","article-title":"Antiangiogenic agents and targets: A perspective","volume":"81","author":"Teicher","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1017\/S0031182000007290","article-title":"Albendazole: A review of anthelmintic efficacy and safety in humans","volume":"121","author":"Horton","year":"2000","journal-title":"Parasitology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.2174\/0929867321666140217105714","article-title":"Benzimidazole derivatives as kinase inhibitors","volume":"21","author":"Garuti","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"10133","DOI":"10.1021\/acs.jmedchem.2c00614","article-title":"Polo-like kinase 1 inhibitors in human cancer therapy: Development and therapeutic potential","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1158\/1078-0432.CCR-10-2946","article-title":"Phase I study of GSK461364, a specific and competitive polo-like kinase 1 inhibitor, in patients with advanced solid malignancies","volume":"17","author":"Olmos","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s41591-021-01391-w","article-title":"Danuglipron (PF-06882961) in type 2 diabetes: A randomized, placebo-controlled, multiple ascending-dose phase 1 trial","volume":"27","author":"Saxena","year":"2021","journal-title":"Nat. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1021\/jm901272d","article-title":"Design, synthesis, and docking studies of novel benzimidazoles for the treatment of metabolic syndrome","volume":"53","author":"Mizuno","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1016\/j.bmc.2008.02.020","article-title":"N-1H-Benzimidazol-5-ylbenzenesulfonamide derivatives as potent hPXR agonists","volume":"16","author":"Benod","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1021\/jm501239f","article-title":"Discovery and development of galeterone (TOK-001 or VN\/124-1) for the treatment of all stages of prostate cancer","volume":"58","author":"Njar","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1021\/jm400033f","article-title":"Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)1H-benzotriazole-5-carboxylic acid and structural development to increase potency","volume":"56","author":"Ohsawa","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1016\/j.bmcl.2009.06.062","article-title":"FXR agonist activity of conformationally constrained analogs of GW 4064","volume":"19","author":"Bass","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6154","DOI":"10.1016\/j.bmcl.2011.08.034","article-title":"Conformationally constrained farnesoid X receptor (FXR) agonists: Alternative replacements of the stilbene","volume":"21","author":"Caravella","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jhep.2023.07.034","article-title":"FXR agonists in NASH treatment","volume":"79","author":"Adorini","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Fujimori, K., Iguchi, Y., Yamashita, Y., Gohda, K., and Teno, N. (2019). Synthesis of novel farnesoid X receptor agonists and validation of their efficacy in activating differentiation of mouse bone marrow-derived mesenchymal stem cells into osteoblasts. Molecules, 24.","DOI":"10.3390\/molecules24224155"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"128026","DOI":"10.1016\/j.bmcl.2021.128026","article-title":"Design and identification of a new farnesoid X receptor (FXR) partial agonist by computational structure\u2013activity relationship analysis: Ligand-induced H8 helix fluctuation in the ligand-binding domain of FXR may lead to partial agonism","volume":"41","author":"Gohda","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"115512","DOI":"10.1016\/j.bmc.2020.115512","article-title":"N1-Substituted benzimidazole scaffold for farnesoid X receptor (FXR) agonists accompanying prominent selectivity against vitamin D receptor (VDR)","volume":"28","author":"Masuda","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.bmcl.2010.11.039","article-title":"Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes","volume":"21","author":"Richter","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.bmcl.2010.12.123","article-title":"Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties","volume":"21","author":"Richter","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_58","unstructured":"Benson, G.M., Bleicher, K., Grether, U., Martin, R.E., Plancher, J.-M., Richter, H., Taylor, S., and Yang, M. (2009). Benzimidazole Derivatives and Their Use as FXR Agonists. (WO2009\/062874-A2)."},{"key":"ref_59","unstructured":"Benson, G.M., Bleicher, K., Feng, S., Grether, U., Kuhn, B., Martin, R.E., Plancher, J.-M., Richter, H., and Taylor, S. (2010). New Benzimidazole Derivatives. (WO2010\/043513-A1)."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Fujimori, K., Iguchi, Y., Yamashita, Y., Gohda, K., and Teno, N. (2025). FXR activation accelerates early phase of osteoblast differentiation through COX-2-PGE2-EP4 axis in BMP-2-induced mouse mesenchymal stem cells. Molecules, 30.","DOI":"10.3390\/molecules30010058"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"8035","DOI":"10.1021\/jm500937v","article-title":"Extending the structure\u2212activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: Development of a highly potent partial farnesoid X receptor agonist","volume":"57","author":"Merk","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1038\/s41467-019-10853-2","article-title":"Molecular tuning of farnesoid X receptor partial agonism","volume":"10","author":"Merk","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1021\/acschembio.2c00599","article-title":"Mechanistic impact of different ligand scaffolds on FXR modulation suggests avenues to selective modulators","volume":"17","author":"Heering","year":"2022","journal-title":"ACS Chem. Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1021\/acs.jpcb.2c06325","article-title":"Deciphering the structural determinants critical in attaining the FXR patrial agonism","volume":"127","author":"Kumari","year":"2023","journal-title":"J. Phys. Chem. B"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.2147\/DDDT.S64877","article-title":"Nonalcoholic steatohepatitis: Emerging targeted therapies to optimize treatment options","volume":"9","author":"Milic","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1021\/jm400856t","article-title":"Polypharmacology\u2014Foe or Friend?","volume":"56","author":"Peters","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"42801","DOI":"10.1038\/srep42801","article-title":"BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses","volume":"7","author":"Carino","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"9196","DOI":"10.1038\/s41598-021-88493-0","article-title":"Discovery, optimization, and evaluation of non-bile acid FXR\/TGR5 dual agonists","volume":"11","author":"Miyata","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"8369","DOI":"10.1021\/acs.jmedchem.0c00618","article-title":"Design and structural optimization of dual FXR\/PPAR\u03b4 activators","volume":"63","author":"Schierle","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ymgme.2004.07.007","article-title":"T0901317 is a dual LXR\/FXR agonist","volume":"83","author":"Houck","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1002\/cmdc.202100118","article-title":"Development and in vitro profiling of dual FXR\/LTA4H modulators","volume":"16","author":"Schierle","year":"2021","journal-title":"ChemMedChem"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1021\/acs.jmedchem.2c01918","article-title":"Discovery of the first-in-class intestinal restricted FXR and FABP1 dual modulator ZLY28 for the treatment of nonalcoholic fatty liver disease","volume":"66","author":"Ren","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"117073","DOI":"10.1016\/j.bmc.2022.117073","article-title":"Design, synthesis, and biological studies of dual URAT1 inhibitor and FXR agonist based on benzbromarone","volume":"75","author":"Huang","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"7703","DOI":"10.1021\/acs.jmedchem.7b00398","article-title":"A dual modulator of farnesoid X receptor and soluble epoxide hydrolase to counter nonalcoholic steatohepatitis","volume":"60","author":"Schmidt","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"117238","DOI":"10.1016\/j.bmc.2023.117238","article-title":"Discovery of FXR\/PPAR\u03b3 dual partial agonist","volume":"85","author":"Yamashita","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Finamore, C., Festa, C., Fiorillo, B., Di Leva, F.S., Roselli, R., Marchian\u00f2, S., Biagioli, M., Spinelli, L., Fiorucci, S., and Limongelli, V. (2023). Expanding the library of 1,2,4-oxadiazole derivatives: Discovery of new farnesoid X receptor (FXR) antagonists\/pregnane X receptor (PXR) agonists. Molecules, 28.","DOI":"10.3390\/molecules28062840"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1021\/acs.jmedchem.4c02720","article-title":"Discovery of first-in-class FXR and HSD17B13 dual modulator for the treatment of metabolic dysfunction-associated fatty liver disease","volume":"68","author":"Jiao","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"18334","DOI":"10.1021\/acs.jmedchem.4c01651","article-title":"Design, synthesis, and pharmacological evaluation of dual FXR-LIFR modulators for the treatment of liver fibrosis","volume":"67","author":"Rapacciuolo","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1021\/acsptsci.1c00041","article-title":"Differential therapeutic effects of FXR activation, sEH inhibition, and dual FXR\/sEH modulation in NASH in diet-induced obese mice","volume":"4","author":"Schmidt","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1021\/jm201468j","article-title":"Discovery of inhibitors of soluble epoxide hydrolase: A target with multiple potential therapeutic indications","volume":"55","author":"Shen","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijcard.2011.12.062","article-title":"Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction","volume":"167","author":"Kompa","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/cmdc.201900576","article-title":"Dual farnesoid X receptor\/soluble epoxide hydrolase modulators derived from zafirlukast","volume":"15","author":"Schierle","year":"2020","journal-title":"ChemMedChem"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1358\/mf.2002.24.8.705072","article-title":"Experimental approaches to study PPAR\u03b3 agonists as antidiabetic drugs","volume":"24","author":"Silvestrel","year":"2002","journal-title":"Methods Find Exp. Clin. Pharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.str.2007.07.014","article-title":"Partial agonists activate PPARg using a helix 12 independent mechanism","volume":"15","author":"Bruning","year":"2007","journal-title":"Structure"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/gutjnl-2019-318813","article-title":"Epidemiology of chronic liver diseases in the USA in the past three decades","volume":"69","author":"Younossi","year":"2020","journal-title":"Gut"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1021\/jm9804127","article-title":"N-(2-Benzoylphenyl)-L-tyrosine PPARg agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents","volume":"41","author":"Henke","year":"1998","journal-title":"J. Med. Chem."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature09291","article-title":"Obesity-linked phosphorylation of PPAR\u03b3 by Cdk5 is a direct target of the anti-diabetic PPAR\u03b3 ligands","volume":"466","author":"Choi","year":"2010","journal-title":"Nature"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/cmdc.200900067","article-title":"Characterization of new PPAR\u03b3 agonists: Benzimidazole derivatives\u2014The importance of position 2","volume":"4","author":"Goebel","year":"2009","journal-title":"ChemMedChem"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"115992","DOI":"10.1016\/j.ejmech.2023.115992","article-title":"Discovery of 4-aminophenylacetamide derivatives as intestine-specific farnesoid X receptor antagonists for the potential treatment of nonalcoholic steatohepatitis","volume":"264","author":"Chen","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"7037","DOI":"10.1021\/jm3002718","article-title":"Discovery and optimization of 1,3,4-trisubstituted-pyrazolone derivatives as novel, potent, and nonsteroidal farnesoid X receptor (FXR) selective antagonists","volume":"55","author":"Huang","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1038\/ncomms10166","article-title":"Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction","volume":"6","author":"Jiang","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1016\/j.bmc.2018.07.017","article-title":"Structural optimization and in vitro profiling of N-phenylbenzamide based farnesoid X receptor antagonists","volume":"26","author":"Schmidt","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e00390","DOI":"10.1002\/prp2.390","article-title":"Antidyslipidemic potential of a novel farnesoid X receptor antagonist in a hamster model of dyslipidemia: Comparative studies of other nonstatin agents","volume":"6","author":"Shinozawa","year":"2018","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/acsmedchemlett.0c00640","article-title":"Discovery of orally active and nonsteroidal farnesoid X receptor (FXR) antagonist with propensity for accumulation and responsiveness in ileum","volume":"12","author":"Teno","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1016\/j.bmc.2014.04.014","article-title":"Identification of trisubstituted-pyrazol carboxamide analogs as novel and potent antagonists of farnesoid X receptor","volume":"22","author":"Yu","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"13452","DOI":"10.1021\/acs.jmedchem.2c01394","article-title":"Discovery of betulinic acid derivatives as potent intestinal farnesoid X receptor antagonists to ameliorate nonalcoholic steatohepatitis","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"17401","DOI":"10.1021\/acsomega.2c01567","article-title":"Discovery of 9,11-seco-cholesterol derivatives as novel FXR antagonists","volume":"7","author":"Zhou","year":"2022","journal-title":"ACS Omega"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1172\/JCI76738","article-title":"Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease","volume":"125","author":"Jiang","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.bmc.2017.01.040","article-title":"Discovery and optimization of benzimidazole derivatives as a novel chemotype of farnesoid X receptor (FXR) antagonists","volume":"25","author":"Teno","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1021\/acsmedchemlett.7b00363","article-title":"Nonacidic chemotype possessing N-acylated piperidine moiety as potent farnesoid X receptor (FXR) antagonists","volume":"9","author":"Teno","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1021\/jm00229a013","article-title":"Potential histamine H2-receptor antagonists. 3. methylhistamines","volume":"19","author":"Durant","year":"1976","journal-title":"J. Med. Chem."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1021\/jm00217a007","article-title":"Cyanoguanidine-thiourea equivalence in the development of the histamine H2-receptor antagonist, cimetidine","volume":"20","author":"Durant","year":"1977","journal-title":"J. Med. Chem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1016\/j.bmc.2019.04.029","article-title":"Identification of potent farnesoid X receptor (FXR) antagonist showing favorable PK profile and distribution toward target tissues: Comprehensive understanding of structure-activity relationship of FXR antagonists","volume":"27","author":"Teno","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/14756360701425014","article-title":"The role of fluorine in medicinal chemistry","volume":"22","author":"Shah","year":"2007","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"8315","DOI":"10.1021\/acs.jmedchem.5b00258","article-title":"Applications of fluorine in medicinal chemistry","volume":"58","author":"Gillis","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"8712","DOI":"10.1021\/acs.jmedchem.6b00472","article-title":"The \u201cCyclopropyl fragment\u201d is a versatile player that frequently appears in preclinical\/clinical drug molecules","volume":"59","author":"Talele","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_108","first-page":"63","article-title":"Structure-activity relationship of FLG249, farnesoid X receptor (FXR) antagonist","volume":"4","author":"Teno","year":"2025","journal-title":"HIU J. Health Sci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1248\/bpb.b24-00311","article-title":"FXR antagonist FLG249 lowers hepatic triacylglycerol and serum cholesterol level in high-fat diet-induced obese mice","volume":"47","author":"Iguchi","year":"2024","journal-title":"Biol. Pharm. Bull."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1248\/bpb.b25-00095","article-title":"FLG249 exhibits FXR antagonist activity through dissociation of corepressor as well as coactivator with FXR","volume":"48","author":"Iguchi","year":"2025","journal-title":"Biol. Pharm. Bull."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1021\/acsmedchemlett.3c00001","article-title":"Trust your gut: Strategies and tactics for intestinally restricted drugs","volume":"14","author":"Dorel","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3390\/molecules29092022","article-title":"Tailoring FXR modulators for intestinal specificity: Recent progress and insights","volume":"29","author":"Morrison","year":"2024","journal-title":"Molecules"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.3760","article-title":"Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance","volume":"21","author":"Fang","year":"2015","journal-title":"Nat. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S1097-2765(03)00104-7","article-title":"A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR","volume":"11","author":"Downes","year":"2003","journal-title":"Mol. Cell"},{"key":"ref_115","unstructured":"Smith, N.D., Govek, S.P., and Nagasawa, J.Y. (2024, February 11). Farnesoid X Receptor Agonists and Uses Thereof. Available online: https:\/\/patentscope.wipo.int\/search\/en\/detail.jsf?docId=WO2018170166."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2021.01.047","article-title":"A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis","volume":"75","author":"Harrison","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Burkey, J., Kansra, S., Macchiarulo, A., Brouwer, K., Adorini, L., Erickson, M., and Pellicciari, R. (2024, January 5\u20138). Farnesoid X receptor agonist INT-787 exhibits high intestinal localization. Proceedings of the European Association for the Study of the Liver, Poster #THU-316, Milan, Italy.","DOI":"10.1016\/S0168-8278(24)00673-1"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.pharmthera.2018.06.009","article-title":"Progress and challenges of selective farnesoid X receptor modulation","volume":"191","author":"Massafra","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1002\/slct.201904832","article-title":"A review on the modern synthetic approach of benzimidazole candidate","volume":"5","author":"Faheem","year":"2020","journal-title":"ChemistrySelect"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/3\/450\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T05:12:39Z","timestamp":1769749959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/3\/450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":119,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["molecules31030450"],"URL":"https:\/\/doi.org\/10.3390\/molecules31030450","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]}}}